Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CAD 208.49 billion. The enterprise value is 228.40 billion.

Market Cap	208.49B
Enterprise Value	228.40B

Important Dates

The next estimated earnings date is Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.02%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.09%
Owned by Institutions (%)	88.30%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 18.46 and the forward PE ratio is 14.55.

PE Ratio	18.46
Forward PE	14.55
PS Ratio	5.15
PB Ratio	6.98
P/TBV Ratio	n/a
P/FCF Ratio	16.34
P/OCF Ratio	15.48
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.52, with an EV/FCF ratio of 17.90.

EV / Earnings	20.22
EV / Sales	5.66
EV / EBITDA	11.52
EV / EBIT	14.49
EV / FCF	17.90

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 1.16.

Current Ratio	1.45
Quick Ratio	1.10
Debt / Equity	1.16
Debt / EBITDA	1.74
Debt / FCF	2.72
Interest Coverage	11.17

Financial Efficiency

Return on equity (ROE) is 40.71% and return on invested capital (ROIC) is 16.14%.

Return on Equity (ROE)	40.71%
Return on Assets (ROA)	12.57%
Return on Invested Capital (ROIC)	16.14%
Return on Capital Employed (ROCE)	24.59%
Revenue Per Employee	2.30M
Profits Per Employee	641,837
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.39

Taxes

In the past 12 months, Gilead Sciences has paid 2.47 billion in taxes.

Income Tax	2.47B
Effective Tax Rate	17.96%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	24.78
200-Day Moving Average	n/a
Relative Strength Index (RSI)	44.59
Average Volume (20 Days)	6,130

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.29

Income Statement

In the last 12 months, Gilead Sciences had revenue of CAD 40.51 billion and earned 11.30 billion in profits. Earnings per share was 8.95.

Revenue	40.51B
Gross Profit	31.89B
Operating Income	15.84B
Pretax Income	13.77B
Net Income	11.30B
EBITDA	19.69B
EBIT	15.84B
Earnings Per Share (EPS)	8.95

Full Income Statement

Balance Sheet

The company has 11.83 billion in cash and 34.74 billion in debt, giving a net cash position of -20.12 billion.

Cash & Cash Equivalents	11.83B
Total Debt	34.74B
Net Cash	-20.12B
Net Cash Per Share	n/a
Equity (Book Value)	29.89B
Book Value Per Share	24.16
Working Capital	7.77B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 13.47 billion and capital expenditures -703.41 million, giving a free cash flow of 12.76 billion.

Operating Cash Flow	13.47B
Capital Expenditures	-703.41M
Free Cash Flow	12.76B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.72%, with operating and profit margins of 39.09% and 27.88%.

Gross Margin	78.72%
Operating Margin	39.09%
Pretax Margin	33.99%
Profit Margin	27.88%
EBITDA Margin	48.60%
EBIT Margin	39.09%
FCF Margin	31.50%

Dividends & Yields

Gilead Sciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	49.10%
Buyback Yield	-1.02%
Shareholder Yield	-1.02%
Earnings Yield	5.42%
FCF Yield	6.12%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.

Altman Z-Score	3.64
Piotroski F-Score	7